Navitoclax (ABT-263), an orally bioavailable small-molecule inhibitor of BCL-2, BCL-XL, and BCL-W [5], showed signs of clinical antitumor activity in chronic lymphocytic leukemia (CLL). This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.